Bedinvetmab

Bedinvetmab
Monoclonal antibody
Type	Whole antibody
Target	Nerve growth factor (NGF)
Clinical data
Trade names	Librela
AHFS/Drugs.com	Veterinary Use
License data	US DailyMed: Bedinvetmab;
Routes of; administration	Subcutaneous
ATCvet code	QN02BG91 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2171034-69-6;
UNII	1AY63T2BE2;

Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.^[3]^[4]^[5] Librela is sponsored by Zoetis.^[5]^[6]

The most common side effects include increased blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation (dermatitis), rash (erythema) or pain at injection site, vomiting (emesis), and weight loss (anorexia).^[5]

Bedinvetmab was approved for medical use in the European Union in November 2020,^[4] and in the United States in May 2023.^[5]^[6] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.^[5]

Medical uses

Bedinvetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.^[5]^[4]

History

Two field studies were conducted to evaluate the effectiveness of bedinvetmab – one in the United States^[7] and one in the European Union.^[5] Both studies enrolled client-owned dogs diagnosed with osteoarthritis.^[5] Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses.^[5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered with the dog's daily activities.^[5] The weight of evidence from the two field studies demonstrated that bedinvetmab is effective at controlling pain associated with osteoarthritis in dogs when at least two doses are given 28 days apart.^[5]

Society and culture

Names

Bedinvetmab is the international nonproprietary name.^[8]

References

^ "Librela Product information". Health Canada.
^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
^ ^a ^b "Librela (bedinvetmab injection) Injectable Solution Dogs". Zoetis Inc. U.S. Food and Drug Administration. NADA 141-562.
^ ^a ^b ^c ^d "Librela EPAR". European Medicines Agency (EMA). 21 February 2022. Archived from the original on 16 March 2023. Retrieved 13 May 2023.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain". U.S. Food and Drug Administration (FDA). 5 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
^ ^a ^b "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.
^ Krautmann M, Walters R, Cole P, Tena J, Bergeron LM, Messamore J, et al. (October 2021). "Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs". Veterinary Journal. 276: 105733. doi:10.1016/j.tvjl.2021.105733. PMID 34391918.
^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.